ctDNA-Guided Treatment in Colorectal Cancer: Progress and Unanswered Questions
Circulating tumor DNA (ctDNA) testing can identify molecular residual disease (MRD) in patients with colorectal cancer who have no radiographic evidence of cancer following curative-intent treatment. Although its prognostic value is well established, questions remain about how best to use the results to guide treatment, according to Scott Kopetz, MD, PhD, Chair, Colorectal Medical Oncology, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center.
During a presentation at the 2026 Association for Molecular Pathology (AMP) Annual Meeting & Expo in Seattle, Dr. Kopetz reviewed findings from observational studies and randomized trials, along with emerging approaches to treating molecularly detectable disease.
Speaking about ctDNA-detected MRD, Dr. Kopetz said, “This is not a high-risk marker, but really defines molecular persistence of disease. So how we talk about it matters.”
ctDNA Status and Recurrence Risk
Prospective studies have consistently shown that ctDNA positivity following colorectal cancer surgery is associated with poorer outcomes.
In the Japanese GALAXY study, 15.9% of 2,109 patients evaluated during the postoperative MRD window had detectable ctDNA.¹ At 3 years, disease-free survival (DFS) was 83.5% among ctDNA-negative patients compared with 16.7% among ctDNA-positive patients (hazard ratio [HR] = 11.99; P < .0001).
ctDNA status remained strongly prognostic after adjustment for conventional risk factors, including pathologic stage and molecular characteristics.
Dr. Kopetz also discussed findings from the INTERCEPT study showing that ctDNA status can distinguish prognosis across disease stages.² In the study, patients with resected stage IV colorectal cancer who tested ctDNA-negative had better outcomes than patients with stage II disease who remained ctDNA-positive.
Assay sensitivity also varies by recurrence site. Dr. Kopetz said detection has generally been less reliable for lung and peritoneal metastases than for liver metastases, potentially reflecting differences in tumor biology or DNA shedding.
ctDNA-Guided Adjuvant Chemotherapy
In the observational GALAXY study, adjuvant chemotherapy was associated with improved outcomes among ctDNA-positive patients, but no significant benefit was observed among ctDNA-negative patients. Randomized trials have since examined whether ctDNA results can be used to guide chemotherapy decisions. However, these nonrandomized findings cannot establish whether ctDNA status predicts benefit from chemotherapy.
The prospective, observational BESPOKE CRC study also examined how ctDNA results influenced clinical management.³ Testing affected adjuvant treatment decisions in 16.3% of cases, leading to chemotherapy de-escalation in 59.9% of those cases and escalation in 35.7%. Among clinicians whose treatment decisions did not change, 83.8% reported that the results increased their confidence in their existing therapeutic plans.
The DYNAMIC-II trial evaluated ctDNA-guided adjuvant chemotherapy in patients with stage II colon cancer.⁴ The guided approach reduced chemotherapy use from 28% with standard management to 15%. At 2 years, recurrence-free survival was 93.5% in the ctDNA-guided group and 92.4% in the standard-management group, meeting the trial's prespecified noninferiority criteria.
The DYNAMIC-III trial examined a different approach in patients with stage III colon cancer, testing whether chemotherapy could be reduced for those who were ctDNA-negative and intensified for those who were ctDNA-positive.⁵ Among 702 ctDNA-negative patients, ctDNA-guided management substantially reduced chemotherapy intensity, particularly the use of oxaliplatin. However, 3-year recurrence-free survival was 85.3% with ctDNA-guided management vs 88.1% with standard management. The trial did not establish noninferiority. These findings suggest that although ctDNA-guided de-escalation can reduce chemotherapy exposure, its oncologic safety has not been established in patients with stage III colon cancer. Intensifying chemotherapy also failed to improve outcomes among ctDNA-positive patients, with 2-year recurrence-free survival of 51% in the escalated treatment group vs 61% with standard management. The findings highlight the need for alternative treatment strategies, rather than just increasing the intensity of existing chemotherapy regimens in patients with detectable MRD.
Ongoing randomized studies, including CIRCULATE-US (ClinicalTrials.gov identifier NCT05174169), are investigating whether selected ctDNA-negative patients can safely undergo surveillance instead of immediate chemotherapy and whether alternative strategies can improve outcomes among patients with detectable MRD.
Developing Treatments for MRD and Research Pipeline
Beyond guiding chemotherapy decisions, Dr. Kopetz discussed developing treatments specifically for patients with detectable MRD but no radiographic recurrence.
Dr. Kopetz also referenced the U.S. Food and Drug Administration's finalized guidance on using ctDNA as a biomarker in clinical trials of curative-intent treatments for solid tumors. The guidance addresses applications such as patient selection and assessment of treatment response, although ctDNA clearance has not been established as a surrogate for long-term clinical benefit.
One approach involves using ctDNA clearance as an early endpoint in smaller phase II studies to identify treatments for subsequent randomized evaluation. He cautioned, however, that clearance alone does not establish clinical benefit.
Several MRD-directed strategies are being investigated in clinical trials, including immunotherapy, cellular therapies, therapeutic vaccines, and lifestyle interventions.
Dr. Kopetz highlighted a phase I trial evaluating TROP2-directed chimeric antigen receptor natural killer cells combined with cetuximab, as well as a separate trial investigating the anti–CTLA-4 antibody botensilimab plus the IgG4 anti–PD-1 monoclonal antibody balstilimab in patients with microsatellite-stable colorectal cancer. Another randomized study is comparing the investigational cMET-directed antibody-drug conjugate ABBV-400 with active surveillance in patients with persistent MRD following standard treatment.
Dr. Kopetz stressed the importance of maintaining high assay specificity as MRD-directed trials advance, since false-positive results could expose patients to unnecessary treatment. He also noted that the biology of MRD remains poorly understood—particularly, how micrometastatic disease may differ from established metastatic tumors. Still, he sees considerable potential in treating patients with molecularly detectable disease before recurrence becomes visible on imaging. Whether these approaches can prevent recurrence and improve survival remains an open question.
“This is a tremendous opportunity to cure more patients,” Dr. Kopetz concluded.
DISCLOSURES
Dr. Kopetz reported stock or ownership interest with MolecularMatch and Navire, and a consulting or advisory role with Amal Therapeutics, Amgen, AstraZeneca/MedImmune, Bayer Health, Biocartis, Boehringer Ingelheim, Boston Biomedical, Daichi Sankyo, EMD Serono, Genentech, Holy Stone, Ipsen, Karyopharm Therapeutics, Lilly, Merck, Natera, Navire Pharma, Novartis, Pierre Fabre, Rodx Phara, Roche, and Symphogen.
REFERENCES
Nakamura Y, Watanabe J, Akazawa N, et al: ctDNA-based molecular residual disease and survival in resectable colorectal cancer. Nat Med 30:3272-3283, 2024.
Maddalena G, Aziz K, Sun R, et al: Clinical impact of prospective circulating tumour DNA testing for minimal residual disease in colorectal cancer: The INTERCEPT programme experience. Gut October 16, 2026 (early release online).
Shah PK, Aushev VN, Ensor J, et al: Circulating tumor DNA for detection of molecular residual disease (MRD) in patients (pts) with stage II/III colorectal cancer (CRC): Final analysis of the BESPOKE CRC sub-cohort. 2025 ASCO Gastrointestinal Cancers Symposium. Abstract 15. Presented January 25, 2025.
Tie J, Cohen JD, Lahouel K, et al: Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. N Engl J Med 386:2261-2272, 2022.
Tie J, Wang Y, Loree JM, et al: Circulating tumor DNA-guided adjuvant therapy in locally advanced colon cancer: The randomized phase 2/3 DYNAMIC-III trial. Nat Med 31:4291-4300, 2025.